Life Science Washington Institute is one of only 13 accelerators in the nation to partner with BARDA’s DRIVe program to solve challenging problems spanning modern health security threats and daily medical care.
What is BARDA?
Established in 2006, the mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop and procure medical countermeasures, vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products, that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents, and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines, and other products that are considered priorities for responding to and recovering from threats to American national health security. To date, the medical countermeasures and products in this diverse portfolio have received a total of 61 FDA approvals, licensures, or clearances.
To help BARDA be prepared for any public health emergency by identifying and derisking the world’s most promising technologies and capabilities, no matter their origin, towards the development of tomorrow’s medical countermeasures.
To ensure the most effective life-saving medical countermeasures are developed for, available to, and used by everyone who needs them when they need them.
DRIVe Program Areas (Click here to view the full EZ BAA and description of funding opportunities) :
NEW AREAS OF INTEREST
For information on applying for one of the BARDA funding opportunities, visit https://drive.hhs.gov/partner.html
For any questions, more information or to request an informational meeting contact Aylin Kim aylin@lswinstitute.org.
In June 2020, LSW Institute hosted a webinar featuring reverse pitches and information about funding opportunities to address the COVID-19 pandemic. View the webinar recording from June 4, 2020.